Statin therapy for primary prevention of cardiovascular disease

JAMA. 2013 Dec 11;310(22):2451-2. doi: 10.1001/jama.2013.281348.


Clinical question: Do statins reduce rates of cardiovascular events when used for primary prevention?

Bottom line: When used for primary prevention, statins are associated with lower rates of all-cause mortality, major vascular events, and revascularizations compared with placebo. Statin therapy is not associated with increased rates of life-threatening adverse effects such as cancer.

MeSH terms

  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / prevention & control*
  • Evidence-Based Medicine
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Neoplasms / epidemiology
  • Primary Prevention*
  • Randomized Controlled Trials as Topic
  • Risk


  • Hydroxymethylglutaryl-CoA Reductase Inhibitors